Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Other Accumulated Expenses (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed Other Accumulated Expenses for 10 consecutive years, with $52948.0 as the latest value for Q2 2024.

  • On a quarterly basis, Other Accumulated Expenses rose 156.16% to $52948.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $52948.0, a 156.16% increase, with the full-year FY2022 number at $42406.0, down 53.06% from a year prior.
  • Other Accumulated Expenses was $52948.0 for Q2 2024 at Crescent Biopharma, up from $10832.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $260972.0 in Q3 2020 to a low of $10832.0 in Q1 2024.
  • A 5-year average of $106627.4 and a median of $90342.0 in 2021 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 156.16% in 2024; the steepest drop was 80.37% in 2024.
  • Crescent Biopharma's Other Accumulated Expenses stood at $220469.0 in 2020, then crashed by 59.02% to $90342.0 in 2021, then tumbled by 53.06% to $42406.0 in 2022, then plummeted by 61.19% to $16457.0 in 2023, then soared by 221.74% to $52948.0 in 2024.
  • Per Business Quant, the three most recent readings for CBIO's Other Accumulated Expenses are $52948.0 (Q2 2024), $10832.0 (Q1 2024), and $16457.0 (Q3 2023).